Non-Invasive Biomarker of Antibody-Mediated Allograft Rejection

摘要

Disclosed herein are methods for the early, non-invasive diagnosis of antibody-mediated allograft rejection, methods of identifying a population of allograft recipients at risk for developing antibody-mediated rejection and methods of monitoring the treatment of patients for antibody-mediated rejection.

主权项

1. A method of detecting antibody-mediated rejection in an allograft transplant recipient, the method comprising:
determining the concentration of C4d+/CD144+ endothelial microparticles (EMP) in a blood sample obtained from the allograft transplant recipient after transplant; wherein if (i) the concentration of C4d+/Cd144+ EMP in the blood sample is greater than about seven standard deviations above the mean of a reference C4d+/CD144+ EMP concentration from a healthy individual, the allograft transplant recipient has antibody-mediated rejection and treatment for antibody-mediated rejection should be initiated, or (ii) the concentration of C4d+/Cd144+ EMP in the blood sample is less than about seven standard deviations above the mean of a reference C4d+/CD144+ EMP concentration from a healthy individual, the allograft transplant recipient does not have antibody-mediated rejection.